Seeking Alpha

Isis (ISIS) +9.2% after the FDA approved its Kynamro drug to treat HoFH, a rare genetic disorder...

Isis (ISIS) +9.2% after the FDA approved its Kynamro drug to treat HoFH, a rare genetic disorder that causes extremely high cholesterol and heart attacks by the age of 30. While the drug is unlikely to be a blockbuster, it could be the first commercially viable medicine to use antisense technology, which can close down specific genes that cause disease and could have unlimited other uses. Partner Sanofi (SNY) is +1%, while it might also be worth watching antisense peer Sarepta (SRPT).
Comments (1)
  • bil4Bill
    , contributor
    Comments (21) | Send Message
     
    don't just watch srpt.

     

    buy it!
    30 Jan 2013, 06:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|